High-Performance Liquid Chromatography-Fluorescence Detection Method for Ochratoxin A Quantification in Small Mice Sample Volumes: Versatile Application across Diverse Matrices Relevant for Neurodegeneration Research.


Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
03 May 2024
Historique:
received: 14 04 2024
revised: 26 04 2024
accepted: 29 04 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 24 5 2024
Statut: epublish

Résumé

Ochratoxin A (OTA) is a mycotoxin commonly found in various food products, which poses potential health risks to humans and animals. Recently, more attention has been directed towards its potential neurodegenerative effects. However, there are currently no fully validated HPLC analytical methods established for its quantification in mice, the primary animal model in this field, that include pivotal tissues in this area of research, such as the intestine and brain. To address this gap, we developed and validated a highly sensitive, rapid, and simple method using HPLC-FLD for OTA determination in mice tissues (kidney, liver, brain, and intestine) as well as plasma samples. The method was rigorously validated for selectivity, linearity, accuracy, precision, recovery, dilution integrity, carry-over effect, stability, and robustness, meeting the validation criteria outlined by FDA and EMA guidelines. Furthermore, the described method enables the quantification of OTA in each individual sample using minimal tissue mass while maintaining excellent recovery values. The applicability of the method was demonstrated in a repeated low-dose OTA study in Balb/c mice, which, together with the inclusion of relevant and less common tissues in the validation process, underscore its suitability for neurodegeneration-related research.

Identifiants

pubmed: 38787065
pii: toxins16050213
doi: 10.3390/toxins16050213
pii:
doi:

Substances chimiques

Ochratoxins 0
ochratoxin A 1779SX6LUY

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Government of Navarra (Project-43, 2019 modality A) and the and European Regional Develop-ment Fund (ERDF under Operational Program for Navarra, 2014-2020
ID : (Project-43, 2019 modality A)

Auteurs

Elba Beraza (E)

MITOX Research Group, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain.

Maria Serrano-Civantos (M)

MITOX Research Group, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain.

Maria Izco (M)

Laboratory of Molecular Neurobiology, Center for Biomedical Research of La Rioja (CIBIR), Piqueras 98, 26006 Logroño, Spain.

Lydia Alvarez-Erviti (L)

Laboratory of Molecular Neurobiology, Center for Biomedical Research of La Rioja (CIBIR), Piqueras 98, 26006 Logroño, Spain.

Elena Gonzalez-Peñas (E)

MITOX Research Group, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain.

Ariane Vettorazzi (A)

MITOX Research Group, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, Universidad de Navarra, 31008 Pamplona, Spain.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH